To Compare The Effects Of Empagliflozin And Metformin On Serum Vitamin D Levels In Patients With Metabolic Syndrome
Abstract
Background: Metabolic Syndrome (MetS) is a cluster of metabolic conditions with increased risk to cardiovascular disease and type 2 diabetes mellitus T2DM. Recent researches have also proposed a relationship between MetS and vitamin D insufficiency. Empagliflozin and Metformin are commonly prescribed for treating MetS; however, their comparative impact on serum vitamin D level remains unclear. The aim of the study was to assess and compare the impact of empagliflozin and metformin on serum vitamin D levels in patients with MetS.
Methods: A comparative study was carried out involving 100 patients diagnosed with T2DM, who were assigned to receive Empagliflozin (Group A) & Metformin (Group B). The variables, including weight, BMI, waist-hip ratio (WHR), blood pressure, fasting blood sugar (FBS), lipid profile and Serum Vitamin D, were recorded, before and after treatment. Statistical analysis was performed using SPSS v23 to assess group differences.
Results: After treatment, the Metformin group showed significant reduction in weight and BMI (p < 0.05), while Empagliflozin group had greater reduction in WHR and Blood pressure (p < 0.05). glycemic control improved significantly in both groups, with a slightly greater FBS reduction in the metformin group (p < 0.05). Empagliflozin significantly increased Vitamin D levels (p < 0.001), whereas Metformin reduced them.
Conclusion: both drugs improved glycemic control, but Empagliflozin had added benefits on central obesity, blood…
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.